97 related articles for article (PubMed ID: 17458169)
1. New therapeutic targets for antibodies and recombinant proteins in organ transplantation.
Créput C; Durrbach A; Deroure B; Charpentier B
Curr Opin Mol Ther; 2007 Apr; 9(2):153-9. PubMed ID: 17458169
[TBL] [Abstract][Full Text] [Related]
2. Novel humanized anti-CD3 antibodies induce a predominantly immunoregulatory profile in human peripheral blood mononuclear cells.
Silva HM; Vieira PM; Costa PL; Pimentel BM; Moro AM; Kalil J; Maranhão AQ; Coelho V; Brigido MM
Immunol Lett; 2009 Aug; 125(2):129-36. PubMed ID: 19573559
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of protein therapeutics.
De Groot AS; Scott DW
Trends Immunol; 2007 Nov; 28(11):482-90. PubMed ID: 17964218
[TBL] [Abstract][Full Text] [Related]
4. [New therapeutic targets for antibodies and recombinant proteins in organ transplantation].
Charpentier B
Bull Acad Natl Med; 2008 May; 192(5):883-93; discussion 893-4. PubMed ID: 19238779
[TBL] [Abstract][Full Text] [Related]
5. Impaired interleukin-2 synthesis and T cell proliferation following antibody-mediated CD3 and CD2 or CD28 cross-linking in trans: evidence that T cell activation requires the engagement of costimulatory molecules within the immunological synapse.
Watson CL; Furlong SJ; Hoskin DW
Immunol Invest; 2008; 37(1):63-78. PubMed ID: 18214800
[TBL] [Abstract][Full Text] [Related]
6. Novel roles of OX40 in the allograft response.
Demirci G; Li XC
Curr Opin Organ Transplant; 2008 Feb; 13(1):26-30. PubMed ID: 18660703
[TBL] [Abstract][Full Text] [Related]
7. Biologics in organ transplantation.
Page EK; Dar WA; Knechtle SJ
Transpl Int; 2012 Jul; 25(7):707-19. PubMed ID: 22420711
[TBL] [Abstract][Full Text] [Related]
8. Novel immunosuppression: small molecules and biologics.
Yabu JM; Vincenti F
Semin Nephrol; 2007 Jul; 27(4):479-86. PubMed ID: 17616278
[TBL] [Abstract][Full Text] [Related]
9. Prediction of immunogenicity: in silico paradigms, ex vivo and in vivo correlates.
De Groot AS; McMurry J; Moise L
Curr Opin Pharmacol; 2008 Oct; 8(5):620-6. PubMed ID: 18775515
[TBL] [Abstract][Full Text] [Related]
10. Induction of immunological tolerance using monoclonal antibodies: applications to organ transplantation and autoimmune disease.
Bach JF
C R Biol; 2006 Apr; 329(4):260-2. PubMed ID: 16644496
[TBL] [Abstract][Full Text] [Related]
11. Role of extracellular matrix proteins in organ transplantation.
Kupiec-Weglinski JW; Górski A
Arch Immunol Ther Exp (Warsz); 1997; 45(1):7-13. PubMed ID: 9090435
[TBL] [Abstract][Full Text] [Related]
12. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
13. Interleukin 7 receptor alpha as a potential therapeutic target in transplantation.
Racapé M; Vanhove B; Soulillou JP; Brouard S
Arch Immunol Ther Exp (Warsz); 2009; 57(4):253-61. PubMed ID: 19585222
[TBL] [Abstract][Full Text] [Related]
14. Role of NK and NKT cells in solid organ transplantation.
Pratschke J; Stauch D; Kotsch K
Transpl Int; 2009 Sep; 22(9):859-68. PubMed ID: 19386078
[TBL] [Abstract][Full Text] [Related]
15. The analysis of the functions of human B and T cells in humanized NOD/shi-scid/gammac(null) (NOG) mice (hu-HSC NOG mice).
Watanabe Y; Takahashi T; Okajima A; Shiokawa M; Ishii N; Katano I; Ito R; Ito M; Minegishi M; Minegishi N; Tsuchiya S; Sugamura K
Int Immunol; 2009 Jul; 21(7):843-58. PubMed ID: 19515798
[TBL] [Abstract][Full Text] [Related]
16. Action profiles of statins and calcineurin inhibitors during human mixed lymphocyte reaction.
Takahashi HK; Iwagaki H; Yagi T; Kanke T; Liu K; Yoshino T; Tanaka N; Nishibori M
Clin Immunol; 2007 Jun; 123(3):324-32. PubMed ID: 17482516
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effects of everolimus on anti-CD3 antibody-stimulated T-lymphocyte proliferation and interleukin-10 synthesis in stable kidney-transplant patients.
Böhler T; Waiser J; Lichter S; Schumann B; Neumayer HH; Kamar N; Budde K
Cytokine; 2008 Jun; 42(3):306-11. PubMed ID: 18440821
[TBL] [Abstract][Full Text] [Related]
18. Bioreagents in allograft immunosuppression.
Soulillou JP
Adv Nephrol Necker Hosp; 1992; 21():373-86. PubMed ID: 1373557
[No Abstract] [Full Text] [Related]
19. Immunological mechanism underlying the immune response to recombinant human protein therapeutics.
Sauerborn M; Brinks V; Jiskoot W; Schellekens H
Trends Pharmacol Sci; 2010 Feb; 31(2):53-9. PubMed ID: 19963283
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants.
Morera Y; Bequet-Romero M; Ayala M; Lamdán H; Agger EM; Andersen P; Gavilondo JV
Angiogenesis; 2008; 11(4):381-93. PubMed ID: 19034678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
